Biogen Idec's MS Therapy Yields Positive Results in Phase III
By Catherine Shaffer
Friday, January 25, 2013
Biogen Idec Inc.'s peginterferon beta-1a produced a significant reduction in annualized relapse rate in patients with multiple sclerosis according to primary efficacy analysis from a Phase III study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.